NCT05245851 is a NA clinical trial of Opportunistic screening for low BMD in Low Bone Density, sponsored by 16 Bit Inc..

Who is sponsoring NCT05245851?

NCT05245851 is sponsored by 16 Bit Inc..

What drugs are being tested in NCT05245851?

Interventions in NCT05245851: Opportunistic screening for low BMD.

What condition does NCT05245851 study?

NCT05245851 studies Low Bone Density.

Is NCT05245851 still recruiting?

NCT05245851 is currently completed. Last updated 19 August 2025.

Last reviewed 2025-08-19 · How we verify

NCT05245851

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Deployment and Validation of Rho

Completed NA Last updated 19 August 2025

What this trial tests

NA trial testing Opportunistic screening for low BMD in Low Bone Density in 1,146 participants. Completed in 1 October 2023.

Timeline

21 November 2022

Primary endpoint
1 October 2023

1 October 2023

Quick facts

Lead sponsor	16 Bit Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	1,146
Start date	21 November 2022
Primary completion	1 October 2023
Estimated completion	1 October 2023
Sites	2 locations across Canada

Drugs / interventions tested

Opportunistic screening for low BMD

Conditions studied

Low Bone Density — all drugs for Low Bone Density →

Sponsor

16 Bit Inc.

Who can join

50 and older, any sex, with Low Bone Density. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Osteoporosis is a widespread disease characterized by the loss of bone mineral density (BMD). 16 Bit has developed software, called RhoTM, that analyzes various x-rays, performed in patient age 50 and above for any clinical indication, to identify patients with low BMD. RhoTM is intended to function as a pre-screening device for low BMD. This study seeks to assess the clinical performance and impact of implementing RhoTM in real-world settings by analyzing its performance and impact on DXA referrals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Low Bone Density

Currently open trials in the same condition.

NCT05283148 — Sickle Cell Disease (SCD) Bone Pain Study · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05245851 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by 16 Bit Inc.
Last refreshed: 19 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05245851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing